Payment overview · 2025
General Payments
$4,200.02
192 reported records · 25 companies
Healthcare provider profile · identity verified
Rafael A Martinez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · TAMPA, FL · NPI 1629144795
Verified facts
What the public records show
CMS Open Payments records show Rafael A Martinez, M.D. received $4,200.02 in general payments during 2025 across 192 reported records.
GlaxoSmithKline, LLC. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fasenra, Glassia, Nucala, Ofev, Tezspire, Trelegy Ellipta, Xywav.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FASENRA as an associated drug or biological on 40035 records involving 10417 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Fasenra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 1095 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 2001 claims for Trelegy Ellipta by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xywav by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $940.84 | 22.4% | 53 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $490.81 | 11.7% | 22 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $394.98 | 9.4% | 11 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $266.73 | 6.3% | 18 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $233.54 | 5.6% | 8 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $202.50 | 4.8% | 10 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $199.42 | 4.8% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $164.92 | 3.9% | 9 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $154.45 | 3.7% | 5 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $146.15 | 3.5% | 7 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $144.94 | 3.5% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.13 | 2.8% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.51 | 2.6% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $101.04 | 2.4% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $94.48 | 2.2% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $79.37 | 1.9% | 4 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $74.71 | 1.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $60.38 | 1.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.89 | 1.4% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $47.68 | 1.1% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $40.50 | 1.0% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.07 | 0.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.34 | 0.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.36 | 0.4% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $15.28 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,148.64 | 190 |
| Education | $51.38 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $506.60 | 29 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $434.24 | 24 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $400.68 | 18 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $374.22 | 14 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $249.35 | 17 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $233.54 | 8 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $202.50 | 10 | 2025 |
Source payment records
|
|||||
| Image Management Subscription Normalized: image management subscription |
Device | Philips North America LLC | $180.54 | 4 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $164.92 | 9 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $146.15 | 7 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $144.94 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.04 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $101.04 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $94.48 | 3 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $90.71 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $79.37 | 4 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $74.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.94 | 3 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $68.69 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $60.38 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $56.89 | 2 | 2025 |
Source payment records
|
|||||
| TYVASO Normalized: tyvaso |
Drug | United Therapeutics Corporation | $47.68 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.82 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $40.86 | 3 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $18.88 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FASENRA fasenra |
2025 | Fasenra | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GLASSIA glassia |
2025 | Glassia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 119 | exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 2001 | exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FASENRA open payments reported associated product |
CMS Open Payments — General Payments 40035 supporting records · 10417 recipient NPIs · example record 1206131346 |
Fasenra · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
1095 | 302 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
119 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
2001 | 448 |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 4663 | 1139 |
| Montelukast Sodium | Montelukast Sodium | 2779 | 731 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 2001 | 448 |
| Fluticasone Propionate | Fluticasone Propionate | 1563 | 484 |
| Symbicort | Budesonide/Formoterol Fumarate | 1095 | 302 |
| Prednisone | Prednisone | 1067 | 457 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 897 | 255 |
| Azithromycin | Azithromycin | 793 | 386 |
| Spiriva Respimat | Tiotropium Bromide | 685 | 176 |
| Roflumilast | Roflumilast | 648 | 131 |
| Famotidine | Famotidine | 583 | 188 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 582 | 149 |
| Breo Ellipta | Fluticasone/Vilanterol | 578 | 136 |
| Ventolin Hfa | Albuterol Sulfate | 534 | 169 |
| Azelastine Hcl | Azelastine Hcl | 525 | 161 |
| Breyna | Budesonide/Formoterol Fumarate | 351 | 118 |
| Doxycycline Hyclate | Doxycycline Hyclate | 319 | 202 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 251 | 109 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 246 | 54 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 197 | 59 |
| Temazepam | Temazepam | 197 | 64 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 196 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 196 | 104 |
| Incruse Ellipta | Umeclidinium Bromide | 188 | 47 |
| Nystatin | Nystatin | 188 | 77 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 181 | 41 |
| Spiriva Handihaler | Tiotropium Bromide | 180 | 57 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 162 | 62 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 158 | 38 |
| Gabapentin | Gabapentin | 145 | 50 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 143 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 127 | 35 |
| Ofev | Nintedanib Esylate | 119 | 24 |
| Mometasone Furoate | Mometasone Furoate | 105 | 19 |
| Dupixent Syringe | Dupilumab | 98 | 13 |
| Levofloxacin | Levofloxacin | 88 | 68 |
| Dupixent Pen | Dupilumab | 74 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 26 |
| Trazodone Hcl | Trazodone Hcl | 65 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 65 | 24 |
| Omeprazole | Omeprazole | 63 | 23 |
| Xolair | Omalizumab | 63 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 60 | 16 |
| Atrovent Hfa | Ipratropium Bromide | 60 | 11 |
| Fluconazole | Fluconazole | 58 | 41 |
| Megestrol Acetate | Megestrol Acetate | 57 | 17 |
| Losartan Potassium | Losartan Potassium | 54 | 22 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 53 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 53 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 39 |
| Eliquis | Apixaban | 49 | 14 |
| Dulera | Mometasone/Formoterol | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 13 |
| Bupropion Xl | Bupropion Hcl | 44 | 13 |
| Alprazolam | Alprazolam | 43 | 12 |
| Clonazepam | Clonazepam | 40 | 15 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 37 | suppressed |
| Furosemide | Furosemide | 37 | 13 |
| Glassia | Alpha-1-Proteinase Inhibitor | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Nucala | Mepolizumab | 33 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 32 | 30 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 31 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Tezspire | Tezepelumab-Ekko | 31 | suppressed |
| Belsomra | Suvorexant | 30 | 14 |
| Ryaltris | Olopatadine Hcl/Mometasone | 29 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 28 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 28 | 11 |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Fasenra | Benralizumab | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Epinephrine | Epinephrine | 20 | 11 |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 19 | 16 |
| Lisinopril | Lisinopril | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Benzonatate | Benzonatate | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Voriconazole | Voriconazole | 16 | suppressed |
| Metformin Hcl | Metformin Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fasenra Pen | Benralizumab | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,200.02 · 192 records | GlaxoSmithKline, LLC. | ABRYSVO, ACTHAR, AIRSUPRA, AREXVY, Arikayce, BREZTRI, Brinsupri, COMIRNATY, DUPIXENT, Da Vinci Surgical System, FASENRA, GLASSIA, Hillrom - Vest System Model 105 Home Care, Image Management Subscription, ImmunoCAP, JASCAYD, LUMRYZ, NUCALA, OFEV, OPSUMIT, Ohtuvayre, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, SKYCLARYS, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, TYVASO, Vest Therapy Und, WAKIX, XYWAV, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fasenra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error